Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Moosig

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Die Pharmazie|October 1, 1995
Derivatives of 3-digitoxigenone amidinohydrazone: synthesis and effect on the digitalis receptor of several species. Part 7: Compounds with positive inotropic activityD Heber, S Herzig, F Moosig, et al.
Der Internist|February 10, 2009
[Autoimmune vasculitides. Standards and guidelines of EULAR and EUVAS]F Moosig, J U Holle, W L Gross, et al.
Zeitschrift Fur Rheumatologie|November 14, 2014
[Polyarteritis nodosa: differential diagnostics and therapy]J H Schirmer, K Holl-Ulrich, F Moosig
Lupus|October 7, 2004
IL-1RA in refractory systemic lupus erythematosusF Moosig, R Zeuner, C Renk, et al.
Clinical and Experimental Immunology|October 9, 1998
Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cellsF Moosig, E Csernok, G Wang, et al.
Der Radiologe|March 31, 2009
[Large-vessel vasculitis. Imaging and interventional therapy]M Both, F Moosig, W L Gross, et al.
Clinical and Experimental Immunology|December 21, 2000
Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-alpha)F Moosig, E Csernok, G Kumanovics, et al.
Der Internist|March 5, 2013
[Hypereosinophilic syndrome]F Moosig, G Richardt, C Merten, et al.
Zeitschrift Fur Rheumatologie|March 7, 2014
[Atrial myxoma with clinical signs of systemic inflammatory disease]I Hartig, E-G Kraatz, H-W Beurich, et al.
Arthritis and Rheumatism|March 20, 1998
Limitations on the usefulness of procalcitonin as a marker of infection in patients with systemic autoimmune disease: comment on the article by Eberhard et alF Moosig, E Reinhold-Keller, E Csernok, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Die Pharmazie|October 1, 1995
Derivatives of 3-digitoxigenone amidinohydrazone: synthesis and effect on the digitalis receptor of several species. Part 7: Compounds with positive inotropic activityD Heber, S Herzig, F Moosig, et al.
Der Internist|February 10, 2009
[Autoimmune vasculitides. Standards and guidelines of EULAR and EUVAS]F Moosig, J U Holle, W L Gross, et al.
Zeitschrift Fur Rheumatologie|November 14, 2014
[Polyarteritis nodosa: differential diagnostics and therapy]J H Schirmer, K Holl-Ulrich, F Moosig
Lupus|October 7, 2004
IL-1RA in refractory systemic lupus erythematosusF Moosig, R Zeuner, C Renk, et al.
Clinical and Experimental Immunology|October 9, 1998
Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cellsF Moosig, E Csernok, G Wang, et al.
Der Radiologe|March 31, 2009
[Large-vessel vasculitis. Imaging and interventional therapy]M Both, F Moosig, W L Gross, et al.
Clinical and Experimental Immunology|December 21, 2000
Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-alpha)F Moosig, E Csernok, G Kumanovics, et al.
Der Internist|March 5, 2013
[Hypereosinophilic syndrome]F Moosig, G Richardt, C Merten, et al.
Zeitschrift Fur Rheumatologie|March 7, 2014
[Atrial myxoma with clinical signs of systemic inflammatory disease]I Hartig, E-G Kraatz, H-W Beurich, et al.
Arthritis and Rheumatism|March 20, 1998
Limitations on the usefulness of procalcitonin as a marker of infection in patients with systemic autoimmune disease: comment on the article by Eberhard et alF Moosig, E Reinhold-Keller, E Csernok, et al.
Pageof 7